Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (22267)	6/15/1998 4:16:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

Lgnd's pipeline is diverse but I think you will agree that the street really doens't seem to care about their pipeline. LGnd's pipeline is as good as the number of drugs that get approved and then are used. It's nice that their first drug has a very good shot of getting approved, but it targets a group that is dwindling which isn't good. CTCL is a horrible disease but not one that, imho, will generate huge amount of profits like say Epogen. Maybe Targetin will do so if it gets approved, but I don't think the street is all that excited about lgnd even thought there are firms with stong buys out there which they have had strong buys out for a long time.